ANI Pharmaceuticalsは275年第4四半期に275万ドルと247億ドルの純利益と29.6%の売上高を記録し,2026年の見通しを向上させた. ANI Pharmaceuticals posted strong Q4 2025 results, with $27.5M net income and $247.1M revenue, up 29.6%, and raised 2026 outlook.

ANI Pharmaceuticalsは,昨年の損失から275万ドルの純利益と2.33ドルの調整後1株当たり利益で,強力なQ4 2025の業績を報告した. ANI Pharmaceuticals reported strong Q4 2025 results, with net income of $27.5 million and adjusted earnings per share of $2.33, up from a loss last year. 売上高は29.6%増加し,推定額を上回る2億4710万ドルとなった. Revenue rose 29.6% to $247.1 million, surpassing estimates. 同社は2026年の見通しを再確認し,収益が10億ドルを超え,EPSは8.83ドルから9.34ドルの間に調整した. The company reaffirmed its 2026 outlook, projecting over $1 billion in revenue and adjusted EPS between $8.83 and $9.34. 成長の要因は 珍しい病気とジェネリックセグメント,特に コートロフィンジェルで 売上高が大きく増加した. Growth was driven by its rare disease and generics segments, particularly Cortrophin Gel, which saw significant sales increases. 同社は前年度の損失にもかかわらず,調整されたEBITDA(EBITDA)と14.11%の 手術余白で30.6%の上昇を表明した. Despite a prior-year loss, the company posted a 30.6% rise in adjusted EBITDA and a 14.1% operating margin. 2026年2月27日の市場前取引で株価は7.6%上昇した. Shares rose 7.6% in pre-market trading on February 27, 2026.